Correlation Between Processa Pharmaceuticals and Akari Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Processa Pharmaceuticals and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Processa Pharmaceuticals and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Processa Pharmaceuticals and Akari Therapeutics PLC, you can compare the effects of market volatilities on Processa Pharmaceuticals and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Processa Pharmaceuticals with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Processa Pharmaceuticals and Akari Therapeutics.

Diversification Opportunities for Processa Pharmaceuticals and Akari Therapeutics

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Processa and Akari is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Processa Pharmaceuticals and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Processa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Processa Pharmaceuticals are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Processa Pharmaceuticals i.e., Processa Pharmaceuticals and Akari Therapeutics go up and down completely randomly.

Pair Corralation between Processa Pharmaceuticals and Akari Therapeutics

Given the investment horizon of 90 days Processa Pharmaceuticals is expected to generate 0.55 times more return on investment than Akari Therapeutics. However, Processa Pharmaceuticals is 1.83 times less risky than Akari Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Akari Therapeutics PLC is currently generating about -0.23 per unit of risk. If you would invest  116.00  in Processa Pharmaceuticals on September 1, 2024 and sell it today you would earn a total of  0.00  from holding Processa Pharmaceuticals or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Processa Pharmaceuticals  vs.  Akari Therapeutics PLC

 Performance 
       Timeline  
Processa Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Akari Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Processa Pharmaceuticals and Akari Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Processa Pharmaceuticals and Akari Therapeutics

The main advantage of trading using opposite Processa Pharmaceuticals and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Processa Pharmaceuticals position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.
The idea behind Processa Pharmaceuticals and Akari Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios